American Heart Association: New Heart Clinical Trial to Shine Light on Early Atrial Fibrillation Treatment
October 27, 2021
October 27, 2021
DALLAS, Texas, Oct. 27 (TNSOps) -- The American Heart Association issued the following news release:
Until now, scientific research about treatment for the most common type of heart arrythmia, atrial fibrillation (AFib), has primarily focused on patients with already established cases of the condition. CHANGE AFib, a new pragmatic clinical trial, will determine whether early treatment with the antiarrhythmic drug dronedarone improves cardiovascular and long-term outcomes in patients . . .
Until now, scientific research about treatment for the most common type of heart arrythmia, atrial fibrillation (AFib), has primarily focused on patients with already established cases of the condition. CHANGE AFib, a new pragmatic clinical trial, will determine whether early treatment with the antiarrhythmic drug dronedarone improves cardiovascular and long-term outcomes in patients . . .